LT3344B - Cetirizine-containing antialergic solution for opthalmic or nasal use - Google Patents

Cetirizine-containing antialergic solution for opthalmic or nasal use Download PDF

Info

Publication number: LT3344B
Authority: LT; Lithuania
Prior art keywords: cetirizine; cyclodextrin; solution; allergic; allergic composition
Prior art date: 1992-12-25

Application number

LTIP1669A

Other languages

English (en)

Lithuanian (lt)

Inventor

Yohifumi Ikejiri

Takahiro Ogawa

Fuminori Tokumochi

Shogo Sameshima

Motoko Kimura

Original Assignee

Senju Pharma Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-12-25

Filing date

1993-12-23

Publication date

1995-07-25

1993-12-23 Application filed by Senju Pharma Co filed Critical Senju Pharma Co

1994-10-25 Publication of LTIP1669A publication Critical patent/LTIP1669A/xx

1995-07-25 Publication of LT3344B publication Critical patent/LT3344B/lt

Links

ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 title abstract description 81
229960001803 cetirizine Drugs 0.000 title abstract description 40
239000000203 mixture Substances 0.000 claims abstract description 75
229920000858 Cyclodextrin Polymers 0.000 claims abstract description 46
230000003266 anti-allergic effect Effects 0.000 claims abstract description 38
-1 cyclodextrin compound Chemical class 0.000 claims abstract description 23
229920003169 water-soluble polymer Polymers 0.000 claims abstract description 12
239000004094 surface-active agent Substances 0.000 claims abstract description 11
239000004480 active ingredient Substances 0.000 claims abstract description 7
150000003839 salts Chemical class 0.000 claims abstract description 7
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 17
239000001116 FEMA 4028 Substances 0.000 claims description 16
229960004853 betadex Drugs 0.000 claims description 16
235000011175 beta-cyclodextrine Nutrition 0.000 claims description 15
210000003928 nasal cavity Anatomy 0.000 claims description 12
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
229920002678 cellulose Polymers 0.000 claims description 4
239000001913 cellulose Substances 0.000 claims description 4
235000010980 cellulose Nutrition 0.000 claims description 4
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 4
229940080345 gamma-cyclodextrin Drugs 0.000 claims description 4
229920005862 polyol Polymers 0.000 claims description 4
150000003077 polyols Chemical class 0.000 claims description 4
229920002554 vinyl polymer Polymers 0.000 claims description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
229920013820 alkyl cellulose Polymers 0.000 claims description 3
239000004359 castor oil Substances 0.000 claims description 3
235000019438 castor oil Nutrition 0.000 claims description 3
150000001875 compounds Chemical class 0.000 claims description 3
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 3
229920000609 methyl cellulose Polymers 0.000 claims description 3
239000001923 methylcellulose Substances 0.000 claims description 3
235000010981 methylcellulose Nutrition 0.000 claims description 3
TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 3
239000002736 nonionic surfactant Substances 0.000 claims description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
229920000053 polysorbate 80 Polymers 0.000 claims description 3
229940068968 polysorbate 80 Drugs 0.000 claims description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
239000000243 solution Substances 0.000 description 75
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
210000001508 eye Anatomy 0.000 description 45
229960004342 cetirizine hydrochloride Drugs 0.000 description 40
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
239000012153 distilled water Substances 0.000 description 26
230000007794 irritation Effects 0.000 description 20
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 18
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 14
239000004327 boric acid Substances 0.000 description 14
229960002645 boric acid Drugs 0.000 description 14
239000003814 drug Substances 0.000 description 14
238000009472 formulation Methods 0.000 description 14
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 13
241000283973 Oryctolagus cuniculus Species 0.000 description 12
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 12
229940079593 drug Drugs 0.000 description 12
229940043377 alpha-cyclodextrin Drugs 0.000 description 11
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
230000000622 irritating effect Effects 0.000 description 10
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 10
238000012360 testing method Methods 0.000 description 10
229960001340 histamine Drugs 0.000 description 9
241000700159 Rattus Species 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000007864 aqueous solution Substances 0.000 description 8
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 7
239000002904 solvent Substances 0.000 description 7
206010010741 Conjunctivitis Diseases 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 6
230000005856 abnormality Effects 0.000 description 6
230000001387 anti-histamine Effects 0.000 description 6
239000000739 antihistaminic agent Substances 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
210000000744 eyelid Anatomy 0.000 description 6
238000000034 method Methods 0.000 description 6
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 5
206010030113 Oedema Diseases 0.000 description 5
230000000694 effects Effects 0.000 description 5
210000002850 nasal mucosa Anatomy 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
229960004926 chlorobutanol Drugs 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
210000004877 mucosa Anatomy 0.000 description 4
229940100656 nasal solution Drugs 0.000 description 4
210000001331 nose Anatomy 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
206010015946 Eye irritation Diseases 0.000 description 3
239000000654 additive Substances 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
229960000686 benzalkonium chloride Drugs 0.000 description 3
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
231100000013 eye irritation Toxicity 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
231100000021 irritant Toxicity 0.000 description 3
239000002085 irritant Substances 0.000 description 3
229960003511 macrogol Drugs 0.000 description 3
239000000463 material Substances 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
229940023490 ophthalmic product Drugs 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000010792 warming Methods 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
241000283977 Oryctolagus Species 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
229940124274 edetate disodium Drugs 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000012528 membrane Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
235000019796 monopotassium phosphate Nutrition 0.000 description 2
231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 2
231100000344 non-irritating Toxicity 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
229960004063 propylene glycol Drugs 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
210000000162 simple eye Anatomy 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000012085 test solution Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010027654 Allergic conditions Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
208000030880 Nose disease Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000035868 Vascular inflammations Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000003732 agents acting on the eye Substances 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
239000000043 antiallergic agent Substances 0.000 description 1
229940054021 anxiolytics diphenylmethane derivative Drugs 0.000 description 1
208000024998 atopic conjunctivitis Diseases 0.000 description 1
210000005252 bulbus oculi Anatomy 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000001816 cooling Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical class C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000003560 epithelium corneal Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
206010015915 eye discharge Diseases 0.000 description 1
208000027993 eye symptom Diseases 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000003118 histopathologic effect Effects 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000002483 medication Methods 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
231100000017 mucous membrane irritation Toxicity 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
231100000323 severe irritant Toxicity 0.000 description 1
238000002791 soaking Methods 0.000 description 1
229960004249 sodium acetate Drugs 0.000 description 1
229960002668 sodium chloride Drugs 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000013112 stability test Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LTIP1669A 1992-12-25 1993-12-23 Cetirizine-containing antialergic solution for opthalmic or nasal use LT3344B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP34603192		1992-12-25

Publications (2)

Publication Number	Publication Date
LTIP1669A LTIP1669A (en)	1994-10-25
LT3344B true LT3344B (en)	1995-07-25

Family

ID=18380671

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTIP1669A LT3344B (en)	1992-12-25	1993-12-23	Cetirizine-containing antialergic solution for opthalmic or nasal use

Country Status (23)

Country	Link
US (1)	US5419898A (fr)
EP (1)	EP0605203B1 (fr)
JP (1)	JP3683595B2 (fr)
KR (1)	KR100276743B1 (fr)
CN (1)	CN1050514C (fr)
AT (1)	ATE164068T1 (fr)
AU (1)	AU666413B2 (fr)
BG (1)	BG61101B1 (fr)
CA (1)	CA2112014C (fr)
CZ (1)	CZ283029B6 (fr)
DE (1)	DE69317537T2 (fr)
DK (1)	DK0605203T3 (fr)
ES (1)	ES2115733T3 (fr)
FI (1)	FI111805B (fr)
HU (2)	HU218672B (fr)
LT (1)	LT3344B (fr)
LV (1)	LV10688B (fr)
NO (2)	NO934630D0 (fr)
NZ (1)	NZ250519A (fr)
PL (1)	PL173347B1 (fr)
RU (1)	RU2130774C1 (fr)
SK (1)	SK279503B6 (fr)
TW (1)	TW401300B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5897858A (en)	1994-02-03	1999-04-27	Schering-Plough Healthcare Products, Inc.	Nasal spray compositions exhibiting increased retention in the nasal cavity
EP0780127A1 (fr) *	1995-12-19	1997-06-25	The Procter & Gamble Company	Pulvérisateur nasale contenant un stéréoide et un antihistamine
US5976573A (en) *	1996-07-03	1999-11-02	Rorer Pharmaceutical Products Inc.	Aqueous-based pharmaceutical composition
WO1998013001A1 (fr) *	1996-09-27	1998-04-02	Nastech Pharmaceutical Company, Inc.	Formulations intranasales pour favoriser le sommeil et leur procede d'utilisation
BE1011251A3 (fr) *	1997-07-03	1999-06-01	Ucb Sa	Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
EP0919550A1 (fr) *	1997-11-26	1999-06-02	Ucb, S.A.	Formes pseudopolymorphiques de l'acide 2-2-4-bis(4-fluorophényl)méthyl -1-pipérazinyl-éthoxy acétique dihydrochloride
DE19814256A1 (de) *	1998-03-31	1999-10-07	Asta Medica Ag	Feste, schnellzerfallende Cetirizin-Formulierungen
IT1303671B1 (it) *	1998-07-28	2001-02-23	Nicox Sa	Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
US20030059440A1 (en) *	1998-09-01	2003-03-27	Tim Clarot	Composition and method for moisturizing nasal tissue
WO2000012137A1 (fr)	1998-09-02	2000-03-09	Allergan Sales, Inc.	Compositions contenant de la cyclodextrine et un agent conservateur
BR9804993A (pt) *	1998-11-10	2000-06-06	Panacea Biotec Ltd	Composição antialérgica e antiinflamatória
JP2001125052A (ja) *	1999-10-25	2001-05-11	Lion Corp	コンタクトレンズ装着液
US6258814B1 (en) *	2000-10-13	2001-07-10	Schering Corporation	Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
NZ534039A (en) *	2002-01-15	2006-08-31	Ucb Farchim S	Formulations of pharmaceutical compositions for oral administration
AR038299A1 (es) *	2002-01-18	2005-01-12	Novartis Ag	Metodos para conservar soluciones oftalmicas y soluciones oftalmicas conservadas.
JP4543274B2 (ja) *	2002-10-01	2010-09-15	大正製薬株式会社	点鼻剤組成物
US6933289B2 (en)	2003-07-01	2005-08-23	Allergan, Inc.	Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20070020299A1 (en) *	2003-12-31	2007-01-25	Pipkin James D	Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20050255154A1 (en) *	2004-05-11	2005-11-17	Lena Pereswetoff-Morath	Method and composition for treating rhinitis
US8216610B2 (en) *	2004-05-28	2012-07-10	Imaginot Pty Ltd.	Oral paracetamol formulations
EP3216445A1 (fr) *	2004-05-28	2017-09-13	Imaginot Pty Ltd.	Système d'administration d'un composé thérapeutique oral
JP2006008568A (ja) *	2004-06-24	2006-01-12	Cyclochem:Kk	ＩｇＥ抗体抑制剤および食品
PE20060484A1 (es) *	2004-07-14	2006-07-06	Ucb Farchim Sa	Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
ATE464883T1 (de) *	2004-07-22	2010-05-15	Bend Res Inc	Geschmacksabdeckende formulierung mit einer retardierten wirkstoffformulierung und/oder schnell löslichem cyclodextrin
AU2006249866B2 (en)	2005-05-26	2011-10-13	Aldeyra Therapeutics, Inc.	Compositions and methods of treating retinal disease
JPWO2006137433A1 (ja) *	2005-06-21	2009-01-22	わかもと製薬株式会社	レボカバスチンを可溶化させた水性薬剤
CA2629904C (fr) *	2005-11-28	2018-07-10	Imaginot Pty Ltd.	Systeme d'administration orale de compose therapeutique
JPWO2007105691A1 (ja) *	2006-03-13	2009-07-30	株式会社アールテック・ウエノ	水性組成物
WO2008025560A1 (fr) *	2006-09-01	2008-03-06	Pari Pharma Gmbh	Procédés servant à masquer le goût de compositions nébulisées pour thérapie par inhalation nasale et pulmonaire
CN101284026B (zh) *	2007-04-12	2010-11-10	鲁南制药集团股份有限公司	一种用于治疗皮肤过敏性疾病的药物组合物
US12370352B2 (en)	2007-06-28	2025-07-29	Cydex Pharmaceuticals, Inc.	Nasal and ophthalmic delivery of aqueous corticosteroid solutions
US9358242B2 (en) *	2007-08-30	2016-06-07	Prelief Inc.	Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
EP2408453B1 (fr) *	2009-03-17	2022-01-05	Nicox Ophthalmics, Inc.	Formulations ophtalmiques de cétirizine et procédés d'utilisation
US8569273B2 (en) *	2009-03-17	2013-10-29	Aciex Therapeutics, Inc.	Ophthalmic formulations of cetirizine and methods of use
US8263581B2 (en) *	2009-07-03	2012-09-11	Jdp Therapeutics, Inc.	Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en)	2009-07-03	2013-08-20	Jdp Therapeutics, Inc.	Non-sedating antihistamine injection formulations and methods of use thereof
AU2010282099B2 (en) *	2009-08-12	2012-12-06	Lunan Better Pharmaceutical Co., Ltd.	Pharmaceutical solution of cetirizine hydrochloride
CA2780151A1 (fr)	2009-11-06	2011-05-12	Yale University	Compositions amphiphiles et procedes de preparation utilisant celles-ci
WO2011072141A1 (fr)	2009-12-11	2011-06-16	Neuron Systems, Inc.	Compositions et procédés pour le traitement de la dégénérescence maculaire
SG11201401597TA (en) *	2011-11-29	2014-05-29	Jurox Pty Ltd	Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
CN117045653A (zh)	2013-01-23	2023-11-14	奥尔德拉医疗公司	与毒性醛相关的疾病和治疗
US10550085B2 (en)	2015-08-21	2020-02-04	Aldeyra Therapeutics, Inc.	Deuterated compounds and uses thereof
KR20180116416A (ko) *	2016-02-28	2018-10-24	알데이라 테라퓨틱스, 아이엔씨.	사이클로덱스트린으로의 알레르기성 안질환의 치료
CA3022665A1 (fr)	2016-05-09	2017-11-16	Aldeyra Therapeutics, Inc.	Polytherapie de troubles et de maladies inflammatoires oculaires
US11241426B2 (en)	2017-02-13	2022-02-08	Nitto Medic Co., Ltd.	Aqueous composition for ophthalmic or nasal administration
CA3054811A1 (fr)	2017-03-16	2018-09-20	Aldeyra Therapeutics, Inc.	Composes polymorphes et leurs utilisations
WO2019075136A1 (fr)	2017-10-10	2019-04-18	Aldeyra Therapeutics, Inc.	Traitement de troubles inflammatoires
HUE054594T2 (hu) *	2018-01-18	2021-09-28	Faes Farma Sa	Bilasztint, béta-ciklodextrint és legalább egy gélesítõszert tartalmazó szemészeti kompozíciók
AU2019319740A1 (en)	2018-08-06	2021-03-25	Aldeyra Therapeutics, Inc.	Polymorphic compounds and uses thereof
EP3856478A4 (fr)	2018-09-25	2022-06-08	Aldeyra Therapeutics, Inc.	Formulations pour le traitement de la maladie de l'oeil sec
US11786518B2 (en)	2019-03-26	2023-10-17	Aldeyra Therapeutics, Inc.	Ophthalmic formulations and uses thereof
EP3725298A1 (fr) *	2019-04-16	2020-10-21	Faes Farma, S.A.	Compositions pharmaceutiques stables et préservées de bilastine
WO2020223717A1 (fr)	2019-05-02	2020-11-05	Aldeyra Therapeutics, Inc.	Procédé de préparation d'un piégeur d'aldéhyde et d'intermédiaires
JP2022530967A (ja)	2019-05-02	2022-07-05	アルデイラセラピューティクス，インコーポレイテッド	多形化合物およびその使用
WO2021231792A1 (fr)	2020-05-13	2021-11-18	Aldeyra Therapeutics, Inc.	Formulations pharmaceutiques et leurs utilisations
CN120437087A (zh)	2024-02-01	2025-08-08	科赴品牌有限责任公司	一种口腔溶解膜制剂、其用途及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06311353A (ja)	1993-04-19	1994-11-04	Brother Ind Ltd	カラー画像形成装置
JPH09339A (ja)	1996-06-17	1997-01-07	Kyushu Hitachi Maxell Ltd	電動式爪みがき機

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI75816C (fi) *	1981-02-06	1988-08-08	Ucb Sa	Foerfarande foer framstaellning av terapeutiskt aktiv 2-/4-(difenylmetyl)-1-piperazinyl/-aettiksyror eller dess amid.
US4556660A (en) *	1982-07-12	1985-12-03	Janssen Pharmaceutica N.V.	N-(Bicyclic heterocyclyl)-4-piperidinamines
NZ224497A (en) *	1987-05-18	1990-04-26	Janssen Pharmaceutica Nv	Pharmaceutical composition comprising flunarizine
US5188826A (en) *	1988-02-08	1993-02-23	Insite Vision Incorporated	Topical ophthalmic suspensions
AU636685B2 (en) *	1989-12-18	1993-05-06	Alcon Laboratories, Inc.	Compositions of antiallergics and antihistamines and methods for their use
US5192780A (en) *	1989-12-18	1993-03-09	Alcon Laboratories, Inc.	Methods using antiallergics and antihistamines
IT1246188B (it) *	1990-07-27	1994-11-16	Resa Farma	Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
DE9015551U1 (de) *	1990-11-14	1992-03-12	Röhm GmbH, 6100 Darmstadt	Orale Arzneiform und Überzugsmittel, enthaltend ein im Colon abbaubares Polysaccarid

1993
- 1993-12-10 TW TW082110475A patent/TW401300B/zh not_active IP Right Cessation
- 1993-12-14 JP JP31295193A patent/JP3683595B2/ja not_active Expired - Fee Related
- 1993-12-15 NO NO934630D patent/NO934630D0/no unknown
- 1993-12-15 NO NO934630A patent/NO304176B1/no unknown
- 1993-12-20 AU AU52597/93A patent/AU666413B2/en not_active Ceased
- 1993-12-20 CZ CZ932836A patent/CZ283029B6/cs not_active IP Right Cessation
- 1993-12-20 NZ NZ250519A patent/NZ250519A/en not_active IP Right Cessation
- 1993-12-20 US US08/169,706 patent/US5419898A/en not_active Expired - Lifetime
- 1993-12-21 CA CA002112014A patent/CA2112014C/fr not_active Expired - Fee Related
- 1993-12-21 PL PL93301588A patent/PL173347B1/pl not_active IP Right Cessation
- 1993-12-22 SK SK1474-93A patent/SK279503B6/sk unknown
- 1993-12-23 FI FI935851A patent/FI111805B/fi active
- 1993-12-23 EP EP93310464A patent/EP0605203B1/fr not_active Expired - Lifetime
- 1993-12-23 BG BG98327A patent/BG61101B1/bg unknown
- 1993-12-23 LT LTIP1669A patent/LT3344B/lt not_active IP Right Cessation
- 1993-12-23 DK DK93310464T patent/DK0605203T3/da active
- 1993-12-23 HU HU9303746A patent/HU218672B/hu not_active IP Right Cessation
- 1993-12-23 DE DE69317537T patent/DE69317537T2/de not_active Expired - Fee Related
- 1993-12-23 AT AT93310464T patent/ATE164068T1/de not_active IP Right Cessation
- 1993-12-23 ES ES93310464T patent/ES2115733T3/es not_active Expired - Lifetime
- 1993-12-24 CN CN93121080A patent/CN1050514C/zh not_active Expired - Fee Related
- 1993-12-24 RU RU93056633A patent/RU2130774C1/ru not_active IP Right Cessation
- 1993-12-24 KR KR1019930029576A patent/KR100276743B1/ko not_active Expired - Fee Related
- 1993-12-24 LV LVP-93-1369A patent/LV10688B/xx unknown
1995
- 1995-06-28 HU HU95P/P00476P patent/HU211972A9/hu unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06311353A (ja)	1993-04-19	1994-11-04	Brother Ind Ltd	カラー画像形成装置
JPH09339A (ja)	1996-06-17	1997-01-07	Kyushu Hitachi Maxell Ltd	電動式爪みがき機

Also Published As

Publication number	Publication date
CN1094614A (zh)	1994-11-09
AU666413B2 (en)	1996-02-08
EP0605203B1 (fr)	1998-03-18
HU9303746D0 (en)	1994-04-28
LV10688A (lv)	1995-06-20
BG98327A (bg)	1994-08-30
NO304176B1 (no)	1998-11-09
EP0605203A2 (fr)	1994-07-06
HU218672B (hu)	2000-10-28
ATE164068T1 (de)	1998-04-15
CA2112014C (fr)	2004-11-02
TW401300B (en)	2000-08-11
FI935851L (fi)	1994-06-26
CA2112014A1 (fr)	1994-06-26
JPH06239748A (ja)	1994-08-30
ES2115733T3 (es)	1998-07-01
HUT69385A (en)	1995-09-28
US5419898A (en)	1995-05-30
NZ250519A (en)	1995-03-28
PL301588A1 (en)	1994-06-27
CN1050514C (zh)	2000-03-22
AU5259793A (en)	1994-07-07
DE69317537T2 (de)	1998-07-09
PL173347B1 (pl)	1998-02-27
LTIP1669A (en)	1994-10-25
NO934630L (no)	1994-06-27
RU2130774C1 (ru)	1999-05-27
DK0605203T3 (da)	1998-12-07
CZ283693A3 (en)	1994-07-13
JP3683595B2 (ja)	2005-08-17
FI935851A0 (fi)	1993-12-23
KR940013511A (ko)	1994-07-15
LV10688B (en)	1995-10-20
HU211972A9 (en)	1996-01-29
EP0605203A3 (fr)	1994-11-02
NO934630D0 (no)	1993-12-15
CZ283029B6 (cs)	1997-12-17
FI111805B (fi)	2003-09-30
KR100276743B1 (ko)	2001-01-15
SK279503B6 (sk)	1998-12-02
BG61101B1 (bg)	1996-11-29
DE69317537D1 (de)	1998-04-23
SK147493A3 (en)	1994-07-06

Legal Events

Date	Code	Title	Description
2010-07-26	MM9A	Lapsed patents	Effective date: 20091223

Publication	Publication Date	Title
LT3344B (en)	1995-07-25	Cetirizine-containing antialergic solution for opthalmic or nasal use
JP2769253B2 (ja)	1998-06-25	水性液剤
KR20090018222A (ko)	2009-02-19	안구 건조의 치료에 있어서 리멕솔론의 용도
BR112019009202A2 (pt)	2020-03-03	Composição para a prevenção ou o tratamento de danos visuais compreendendo ácido ursodeoxicólico
EP0807434B1 (fr)	2002-04-10	Gouttes oculaires anti-inflammatoires
US6403598B1 (en)	2002-06-11	Ophthalmic composition
WO2002040028A1 (fr)	2002-05-23	Gouttes pour les yeux en gel antibacterien
TW304879B (fr)	1997-05-11
NZ264616A (en)	1997-06-24	Compositions for treating myopia containing a 7-alkyl-5-oxo-benzopyrano[2,3-b]pyridine derivative
WO2025169089A1 (fr)	2025-08-14	Compositions ophtalmiques d'inhibiteurs de tyrosine kinase et leurs utilisations
JPH02262518A (ja)	1990-10-25	眼圧調整剤
KR100261585B1 (ko)	2000-07-15	항염증점안제
KR20230021613A (ko)	2023-02-14	안구건조증 치료를 위한 레코플라본 함유 점안 조성물 및 이의 제조방법
Xiao et al.	2019	Thermoreversible In Situ Gel for Ophthalmic Delivery of Ciprofloxacin and Betamethasone for the Treatment of Ocular Degenerative Disease: Assesment in Rabbit
Stefánsson et al.	1996	2-Hydroxypropyl-ß-Cyclodextrin in Eye Drops. Evaluation of Artificial Tear-Drops In Human Patients
WO2022156372A1 (fr)	2022-07-28	Préparation ophtalmique administrée par collyre et utilisée pour la prévention et le traitement de la dégénérescence maculaire sèche et de la détérioration de la lumière rétinienne
WO2023048174A1 (fr)	2023-03-30	Agent thérapeutique pour maladie de la cornée